Skip to main content
. 2019 Jun 18;2019(6):CD009354. doi: 10.1002/14651858.CD009354.pub5

Comparison 1. Laronidase versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1.1 Change in urinary GAG excretion 1   Other data No numeric data
1.2 Change from baseline in FVC (% of predicted normal) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.2.1 At week 26 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.3 Change from baseline in 6MWT 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.3.1 At week 26 1 45 Mean Difference (IV, Fixed, 95% CI) 38.10 [‐1.68, 77.88]
1.4 One or more infusion related reactions 1   Odds Ratio (M‐H, Fixed, 95% CI) Totals not selected
1.5 Antibody production 1   Odds Ratio (M‐H, Fixed, 95% CI) Totals not selected
1.6 % change in liver volume 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.6.1 At week 26 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected